Search

Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and indicated by the FDA[sup.1] Recommendation [...]

CHICAGO, IL -- The following information was released by the Society of Gynecological Oncology (SGO): The Society of Gynecologic Oncology (SGO) regrets to announce the passing of past president Peter [...]

LOS ANGELES -- The following information was released by the American Association for Cancer Research (AACR): Symptoms were associated with lower mental quality of life for both Black and white [...]

NEW DELHI, India -- The following information was released by the Government of India: by PIB Delhi Researchers have used a combination of áultra-small magnetic nanoparticles (MDs) along with a [...]

INSTITUTE OF HEALTH OF EMPLOYEES OF THE STATE OF CEARA, Brazil has invited tenders for Medication for Adjuvant Chemotherapy Treatment.. Tender Notice No: 2024/18683 Deadline: August 5, 2024 Copyright © [...]

MINISTRY OF HEALTH AND WELFARE TAICHUNG HOSPITAL, Taiwan has invited tenders for Temporary Purchase of Drugs for Adjuvant Therapy for Breast Cancer. Tender Notice No: TH113097 Deadline: July 1, 2024 [...]

MINISTRY OF HEALTH AND WELFARE TAICHUNG HOSPITAL, Taiwan has invited tenders for Temporary Purchase of Drugs for Adjuvant Therapy for Breast Cancer. Tender Notice No: TH113097 Deadline: June 18, 2024 [...]

2024 OCT 30 (VerticalNews) -- By a News Reporter-Staff News Editor at Education Letter -- New research on Oncology - Breast Cancer is the subject of a report. According to [...]

BALTIMORE: Sysmex Inostics has issued the following news release: Sysmex Inostics Inc., a subsidiary of Japan's Sysmex Corporation and Baltimore-based biotechnology firm and CLIA-certified lab, in collaboration with the University [...]

SEOUL: CanariaBio Inc. has issued the following news release: CanariaBio Inc, a leading late-stage biotechnology company, announces the successful completion of enrollment of 88 patients in a randomized Phase 2 [...]

SEOUL, South Korea, Aug. 23, 2024 /PRNewswire/ -- CanariaBio Inc, a leading late-stage biotechnology company, announces the successful completion of enrollment of 88 patients in a randomized Phase 2 study [...]

WILMINGTON, Del.--(BUSINESS WIRE)--Aug 16, 2024-- AstraZeneca’s IMFINZI ® (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small [...]

SEATTLE: Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study [...]

CHICAGO, IL -- The following information was released by the Society of Gynecological Oncology (SGO): SGO Board of Directors and Communications Committee Member Nora Lersch, DNP, FNP-BC, AOCNP, attended the [...]

Switzerland: Roche Holding AG has issued the following news release: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Alecensa(r) (alectinib) monotherapy, as adjuvant treatment [...]

SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment [...]

The princess said that the cancer had been discovered after abdominal surgery and that she was receiving ''preventative chemotherapy.'' When Catherine, Princess of Wales, revealed on Friday evening that she [...]

Estonia based Ou Antegenes has secured contract from sihtasutus Pohja-Eesti Regionaalhaigla for Laboratory Services - a test to define the optimal adjuvant therapy of breast cancer. The value of the [...]

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 29, 2024-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has [...]

Switzerland: Roche Holding AG has issued the following news release: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa(r) (alectinib) [...]

SOUTH SAN FRANCISCO: Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa(r) (alectinib) for adjuvant treatment following tumor resection for [...]

Data presentation at highly influential American Society of Breast Surgeons ('ASBrS') Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons President-Elect of the ASBrS, [...]

IRVINE: Agendia, Inc. announced that the company's 80-gene molecular subtyping assay, BluePrint, is now included in the latest version of German Gynecological Oncology Group (AGO) guidelines. The assay was added [...]

BURLINGTON, N.C: Labcorp has issued the following news release: Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp(r) Plasma Detecttm, the [...]

RAHWAY: Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with [...]

RAHWAY, N.J.--(BUSINESS WIRE)--Mar 28, 2024-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 [...]

SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies [...]

ROCKVILLE, Md. and SUZHOU, China: Innovent Biologics has issued the following news release: Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality [...]

ROCKVILLE, Md. and SUZHOU, China, March 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the [...]

SEATTLE: Atossa Therapeutics, Inc. announces that the pre-menopausal, Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-), breast cancer patient who received neoadjuvant and adjuvant (Z)-endoxifen [...]

AUSTIN: Natera, Inc. announces a collaboration with the Federation Francophone de Cancerologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical trial in [...]

Byline: Virginia Lawyers Weekly Type of action: Medical malpractice Injuries alleged: Recurrence and mutation of stage IV breast cancer Date resolved: 8/14/2023 Verdict or settlement: Settlement Amount: $1,450,000 Attorneys for [...]

SHANGHAI: Asieris has issued the following news release: Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary [...]

SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and [...]

SHANGHAI: Asieris has issued the following news release: Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary [...]

SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and [...]

RAHWAY: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), [...]

First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma HONGKONG, Dec. 5, 2023 /PRNewswire/ -- Akeso (9926.HK) published results from three investigator-initiated trials (IITs) of [...]

WILMINGTON, Del.--(BUSINESS WIRE)--Nov 17, 2023-- AstraZeneca’s TRUQAP™ (capivasertib) in combination with fulvestrant has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally [...]

PALO ALTO, Calif.--(BUSINESS WIRE)--Oct 23, 2023-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that initial results from the PEGASUS trial suggest liquid biopsy may be [...]

BASEL: BeiGene, Ltd., announced that the Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR) and event-free survival [...]

RAHWAY: Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a monotherapy [...]

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 16, 2023-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 [...]

IRVINE: Agendia has issued the following news release: Agendia(r), Inc., a global leader in innovative genomic technology and diagnostic tests, announced today the publication of the Multi-Institutional Neoadjuvant Therapy MammaPrint [...]

PRINCETON: BRISTOL MYERS SQUIBB has issued the following news release: Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free [...]

SHANGHAI: Asieris has issued the following news release: Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and [...]